RT Journal Article
SR Electronic
T1 No difference in moxifloxacin penetration between infected and uninfected pleural fluid
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P4374
VO 42
IS Suppl 57
A1 Kalliopi Chatzika
A1 Katerina Manika
A1 Paschalina Kontou
A1 Georgia Pitsiou
A1 Konstantinos Zarogoulidis
A1 Ioannis Kioumis
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P4374.abstract
AB Introduction: Moxifloxacin (MXF) is often prescribed for the treatment of pleural space infections. However, there are no existing data on MXF penetration into pleural fluid (PF) in humans.Aims: To compare the kinetics and penetration of MXF in patients with infected and uninfected pleural effusion.Methods: Nine patients with infected effusion (51.8±19.3 years) and ten patients with uninfected effusion (70.9±11.8 years) enrolled the study. All patients received a single intravenous dose of 400 mg MXF. Serial plasma (PL) and PF samples were collected for a 24 hour interval. MXF concentration in PL and PF was determined by high-performance liquid chromatography. The maximum concentration (CmaxPF) was estimated by direct observation of determined values and TmaxPF was the time to reach that concentration. The area under concentration-time curve (AUC24PL and AUC24PF) was calculated by the trapezoidal rule.Results:View this table:No statistically significant differences were observed between two groups in PF Cmax, AUC24 and MXF penetration. The time to reach maximum concentration of MXF in PF was statistically significantly longer in patients with infected effusion.Conclusions: These data demonstrate an equal MXF penetration in both groups and also a remarkable delay in achievement of PF Cmax in patients with pleural space infection.The presence of infection did not affect the degree of MXF penetration and the on-site drug exposure as expressed by the AUC24PF.